High-Risk Neuroblastoma Treatment Review

Overview

Journal Children (Basel)

Specialty Health Services

Date 2018 Aug 30

PMID 30154341

Citations 108

Authors

Valeria Smith

Jennifer Foster

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is the most common extracranial solid tumor in children. One subset, high-risk neuroblastoma, is very difficult to treat and requires multi-modal therapy. Intensification of therapy has vastly improved survival rates, and research is focused on novel treatments to further improve survival rates. The current treatment schema is divided into three stages-induction, consolidation, and maintenance. This review serves as an overview of the current treatment for high-risk neuroblastoma and a glimpse at current research for future therapy.

Citing Articles

Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.

Chu Y, Tian M, Saini U, Ayala-Cuesta J, Klose K, Mendelowitz A Mol Ther Oncol. 2025; 33(1):200927.

PMID: 39895691 PMC: 11783442. DOI: 10.1016/j.omton.2024.200927.

Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?.

Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N Genes Dis. 2025; 12(2):101156.

PMID: 39802403 PMC: 11719324. DOI: 10.1016/j.gendis.2023.101156.

Multicellular model of neuroblastoma proposes unconventional therapy based on multiple roles of p53.

Wertheim K, Chisholm R, Richmond P, Walker D PLoS Comput Biol. 2024; 20(12):e1012648.

PMID: 39715281 PMC: 11723635. DOI: 10.1371/journal.pcbi.1012648.

Iwilfin (eflornithine) approved by the FDA as the first and only oral maintenance therapy for high-risk neuroblastoma in adult and pediatric patients: Narrative review.

Shakeel A, Baloch A, Kumari V, Kazmi S, Aftab K, Abid S Medicine (Baltimore). 2024; 103(48):e40662.

PMID: 39612452 PMC: 11608686. DOI: 10.1097/MD.0000000000040662.

Novel PP2A-Activating Compounds in Neuroblastoma.

Nazam N, Bownes L, Julson J, Quinn C, Erwin M, Marayati R Cancers (Basel). 2024; 16(22).

PMID: 39594793 PMC: 11592631. DOI: 10.3390/cancers16223836.

References

Gaze M, Boterberg T, Dieckmann K, Hormann M, Gains J, Sullivan K . Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: a SIOPEN study. Int J Radiat Oncol Biol Phys. 2012; 85(1):170-4. DOI: 10.1016/j.ijrobp.2012.05.004. View

Cheung N, Cheung I, Kushner B, Ostrovnaya I, Chamberlain E, Kramer K . Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012; 30(26):3264-70. PMC: 3434986. DOI: 10.1200/JCO.2011.41.3807. View

Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View

Mastrangelo S, Rufini V, Ruggiero A, Di Giannatale A, Riccardi R . Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. Pediatr Blood Cancer. 2011; 56(7):1032-40. DOI: 10.1002/pbc.22986. View

Kreissman S, Seeger R, Matthay K, London W, Sposto R, Grupp S . Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013; 14(10):999-1008. PMC: 3963485. DOI: 10.1016/S1470-2045(13)70309-7. View

Ladenstein R, Potschger U, Pearson A, Brock P, Luksch R, Castel V . Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017; 18(4):500-514. DOI: 10.1016/S1470-2045(17)30070-0. View

Casey D, Kushner B, Cheung N, Modak S, LaQuaglia M, Wolden S . Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma. Int J Radiat Oncol Biol Phys. 2016; 96(2):393-400. PMC: 5476959. DOI: 10.1016/j.ijrobp.2016.05.020. View

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R . Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015; 526(7575):700-4. PMC: 4881306. DOI: 10.1038/nature14980. View

10.

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res. 1994; 385:363-9. View

11.

Peinemann F, van Dalen E, Tushabe D, Berthold F . Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015; 1:CD010685. DOI: 10.1002/14651858.CD010685.pub2. View

12.

Lee J, Lee S, Cho H, Ma Y, Yoo K, Sung K . Incorporation of high-dose I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017; 10(1):108. PMC: 5432997. DOI: 10.1186/s13045-017-0477-0. View

13.

Louis C, Shohet J . Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2014; 66:49-63. PMC: 4418018. DOI: 10.1146/annurev-med-011514-023121. View

14.

Peinemann F, Tushabe D, van Dalen E, Berthold F . Rapid COJEC versus standard induction therapies for high-risk neuroblastoma. Cochrane Database Syst Rev. 2015; (5):CD010774. PMC: 10501324. DOI: 10.1002/14651858.CD010774.pub2. View

15.

Pugh T, Morozova O, Attiyeh E, Asgharzadeh S, Wei J, Auclair D . The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-84. PMC: 3682833. DOI: 10.1038/ng.2529. View

16.

Pinto N, Applebaum M, Volchenboum S, Matthay K, London W, Ambros P . Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015; 33(27):3008-17. PMC: 4567703. DOI: 10.1200/JCO.2014.59.4648. View

17.

Qayed M, Chiang K, Ricketts R, Alazraki A, Tahvildari A, Haight A . Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma. Pediatr Blood Cancer. 2011; 58(3):448-52. DOI: 10.1002/pbc.23155. View

18.

Zhou M, Doral M, Dubois S, Villablanca J, Yanik G, Matthay K . Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015; 51(16):2465-72. PMC: 4607645. DOI: 10.1016/j.ejca.2015.07.023. View

19.

Mosse Y, Lim M, Voss S, Wilner K, Ruffner K, Laliberte J . Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14(6):472-80. PMC: 3730818. DOI: 10.1016/S1470-2045(13)70095-0. View

20.

Mazloom A, Louis C, Nuchtern J, Kim E, Russell H, Allen-Rhoades W . Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014; 90(4):858-62. PMC: 5107988. DOI: 10.1016/j.ijrobp.2014.07.019. View